SCHEMBL2016027

SCHEMBL2016027

CCOC(=O)c1ccc(Cl)c(-c2nnc(N3CCc4ccccc4C3C3CC3)c3ccccc23)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
DRD3 P35462 1/20 0.38
KDR P35968 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
OPRM1 P35372 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
LMNA P02545 2/20 0.37
SMO Q99835 1/20 0.37
PDE2A O00408 1/20 0.37
PDE10A Q9Y233 1/20 0.37
POLB P06746 2/20 0.36
ADRB2 P07550 1/20 0.36
HTT P42858 1/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SGPL1 O95470 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2016015 0.73 MEN1 (0.38) ALDH1A1MEN1KMT2ALMNASMO
SCHEMBL2016584 0.65 DRD2 (0.37) ALDH1A1MEN1KMT2AOPRM1OPRK1
SCHEMBL2015235 0.63 NPSR1 (0.40) ALDH1A1MEN1KMT2ASMOHTT
SCHEMBL31336539 0.63 RAB9A (0.63) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL25381781 0.63 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ALMNAPDE2A
SCHEMBL2021655 0.62 MEN1 (0.37) ALDH1A1KDRMEN1KMT2AOPRM1
SCHEMBL7214891 0.61 KCNH2 (0.60) KCNH2CYP1A2
SCHEMBL2017286 0.61 MEN1 (0.36) ALDH1A1MEN1KMT2AOPRM1OPRK1
SCHEMBL7820129 0.61 ADORA2A (0.40) ALDH1A1MEN1KMT2ALMNAHTT
SCHEMBL15463549 0.61 GABRP (0.64) ALDH1A1MEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 ALDH1A1 403/4885DRD3 3906/4885KDR 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.